Trial Profile
A Phase 1/2 Study of HDAC Inhibitor, Mocetinostat, in Combination With PD-L1 Inhibitor, Durvalumab, in Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 30 Mar 2022
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Mocetinostat (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Mirati Therapeutics
- 10 Mar 2021 Study design changed to sequential.
- 10 Mar 2021 According to clinicaltrials.gov the study was discontinued early because the Sponsor de-prioritized development of mocetinostat. The decision to stop was not due to any patient safety issues.
- 10 Mar 2021 Status changed to discontinued.